NanoMnSor reprograms the immunosuppressive TME by reducing the hypoxia-induced tumor TAMs infiltration, promote macrophage polarization to the M1 immunostimulatory phenotype, and increase the number of CD8+ cytotoxic T-cell numbers in tumors, thereby increasing the efficacy of the anti-PD-1 antibody, synergistically inhibited the progression of both primary HCC as well as distant metastases (Chang et al., 2020). The gene discussed is PDCD1; the disease is hepatocellular carcinoma.